326 related articles for article (PubMed ID: 35582023)
1. The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance.
Meng Y; Qiu L; Zhang S; Han J
Cancer Drug Resist; 2021; 4(2):365-381. PubMed ID: 35582023
[TBL] [Abstract][Full Text] [Related]
2. Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.
Yang L; Chen J; Huang X; Zhang E; He J; Cai Z
Am J Med Sci; 2018 Apr; 355(4):368-376. PubMed ID: 29661351
[TBL] [Abstract][Full Text] [Related]
3. Role of E3 ubiquitin ligases in lung cancer.
Snoek BC; de Wilt LH; Jansen G; Peters GJ
World J Clin Oncol; 2013 Aug; 4(3):58-69. PubMed ID: 23936758
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles of the HECT-type E3 ubiquitin ligases in hematological malignancies.
Delvecchio VS; Fierro C; Giovannini S; Melino G; Bernassola F
Discov Oncol; 2021 Oct; 12(1):39. PubMed ID: 35201500
[TBL] [Abstract][Full Text] [Related]
5. Targeting E3 ubiquitin ligases for cancer therapy.
Sun Y
Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
[TBL] [Abstract][Full Text] [Related]
6. E3 ubiquitin ligases as cancer targets and biomarkers.
Sun Y
Neoplasia; 2006 Aug; 8(8):645-54. PubMed ID: 16925947
[TBL] [Abstract][Full Text] [Related]
7. MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.
Lee J; An S; Jung JH; Kim K; Kim JY; An IS; Bae S
Int J Oncol; 2019 May; 54(5):1833-1842. PubMed ID: 30816444
[TBL] [Abstract][Full Text] [Related]
8. A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases.
Tian M; Zeng T; Liu M; Han S; Lin H; Lin Q; Li L; Jiang T; Li G; Lin H; Zhang T; Kang Q; Deng X; Wang HR
J Biol Chem; 2019 Feb; 294(8):2880-2891. PubMed ID: 30587574
[TBL] [Abstract][Full Text] [Related]
9. E3 Ubiquitin Ligases in Breast Cancer Metastasis: A Systematic Review of Pathogenic Functions and Clinical Implications.
Wang Y; Dai J; Zeng Y; Guo J; Lan J
Front Oncol; 2021; 11():752604. PubMed ID: 34745984
[TBL] [Abstract][Full Text] [Related]
10. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
Satija YK; Bhardwaj A; Das S
Int J Cancer; 2013 Dec; 133(12):2759-68. PubMed ID: 23436247
[TBL] [Abstract][Full Text] [Related]
11. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
O'Brien PM; Davies MJ; Scurry JP; Smith AN; Barton CA; Henderson MJ; Saunders DN; Gloss BS; Patterson KI; Clancy JL; Heinzelmann-Schwarz VA; Murali R; Scolyer RA; Zeng Y; Williams ED; Scurr L; Defazio A; Quinn DI; Watts CK; Hacker NF; Henshall SM; Sutherland RL
Br J Cancer; 2008 Mar; 98(6):1085-93. PubMed ID: 18349819
[TBL] [Abstract][Full Text] [Related]
12. Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3.
Hu X; Meng Y; Xu L; Qiu L; Wei M; Su D; Qi X; Wang Z; Yang S; Liu C; Han J
Cell Death Dis; 2019 Feb; 10(2):104. PubMed ID: 30718461
[TBL] [Abstract][Full Text] [Related]
13. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
[TBL] [Abstract][Full Text] [Related]
14. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
Uchida C; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
[TBL] [Abstract][Full Text] [Related]
15. The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer.
Lan H; Yuan J; Zeng D; Liu C; Guo X; Yong J; Zeng X; Xiao S
Front Genet; 2021; 12():693259. PubMed ID: 34512721
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.
Pan WW; Zhou JJ; Yu C; Xu Y; Guo LJ; Zhang HY; Zhou D; Song FZ; Fan HY
J Biol Chem; 2013 Oct; 288(41):29680-91. PubMed ID: 23995842
[TBL] [Abstract][Full Text] [Related]
17. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Masumoto K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
[TBL] [Abstract][Full Text] [Related]
18. DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Li J; Yu T; Yan M; Zhang X; Liao L; Zhu M; Lin H; Pan H; Yao M
Exp Cell Res; 2019 Jan; 374(2):304-314. PubMed ID: 30528265
[TBL] [Abstract][Full Text] [Related]
19. Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges.
Ye P; Chi X; Cha JH; Luo S; Yang G; Yan X; Yang WH
Cells; 2021 Nov; 10(12):. PubMed ID: 34943817
[TBL] [Abstract][Full Text] [Related]
20. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
Liu L; Wong CC; Gong B; Yu J
Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
